Joint inflammation reduction

Joint inflammation reduction" is not the name of a specific molecule, receptor, or therapeutic target. Instead, it describes a *therapeutic goal* or clinical outcome relevant to diseases such as rheumatoid arthritis and other inflammatory joint conditions. The reduction of joint inflammation can be achieved by targeting various molecular pathways and proteins involved in the immune response—such as tumor necrosis factor alpha (TNF), interleukins (e.g., IL‑1, IL‑6), Janus kinases (JAKs), and others[1][2][3][4][7]. Drugs that reduce joint inflammation include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) like methotrexate, biologics targeting TNF or interleukins, and JAK inhibitors[1][2][3][4][7]. However, none of these are called "joint inflammation reduction"; rather they are agents that achieve this effect by acting on specific molecular targets. Therefore: > “Joint inflammation reduction” is not itself a canonical drug target but rather an intended therapeutic effect achieved through modulation of various validated molecular targets involved in inflammatory pathways[1][2].